Clinical trials: SLE
SLE (Systemic Lupus)
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity
Assessment of CXCL5 biomarker in Serum of patients of SLE in comparison to healthy patients and its correlation with disease activity
- Trial name
- NCT06610409
- Testing
- blood sampling
- Where
- Egypt
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Assiut University
Systemic Lupus Erythematosus
Allogeneic Stem Cell Transplantation in Systemic Lupus Erythematosus
This trial is designed to evaluate the safety of treating systemic lupus erythematosus participants with cyclophosphamide and CAMPATH-1H followed by allogeneic stem cell transplant. There will be no randomization in this study.
- Trial name
- NCT00278590
- Testing
- Allogeneic Stem Cell Transplantation
- Where
- United States
- Sponsor
- Northwestern University
Refractory Autoimmune Diseases
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory…
- Trial name
- NCT07115745
- Testing
- BMS-986515, Fludarabine, Cyclophosphamide
- Where
- 28 sites in United States, Australia and 8 more
- Volunteers
- 125 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Systemic Lupus Erythematosus
Efficacy of Synbiotic Supplementation on IL-10, TGF-B and Disease Activity in Systemic Lupus Erythematosus Patients
Dysregulation of normal flora leads to dysbiosis, which has recently been investigated as an important internal environmental factor and has been proven to be associated with both active and remission phases of SLE, and can be…
- Trial name
- ESSENTIAL (NCT07048470)
- Testing
- Synbiotic
- Where
- Indonesia
- Volunteers
- 36 people
- Sponsor
- Universitas Sriwijaya
Systemic Lupus Erythematosus
Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus.
The present study aims to: Compare clinical features, hematological indices and disease activity between the early-onset and late-onset patients with systemic lupus erythematosus.
- Trial name
- NCT06294483
- Testing
- CBC, Antinuclear Antibody tests (ANA), Rest of ANA profile
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Cutaneous Lupus, Systemic Lupus Erythematosus
Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus
This 76-week, 3-part Phase 1b/2 study is intended to evaluate the pharmacological properties (pharmacokinetics and pharmacodynamics), safety, tolerability and preliminary effectiveness of TOFA administrated to young adults (18-45…
- Trial name
- NCT03288324
- Testing
- Tofacitinib
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
System Lupus Erythematosus(SLE)
Anti-CD19 CAR-T Cell Therapy for Patients With Refractory Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by B-cell dysfunction leading to the production of autoantibodies that play a key role in the onset and progression of the disease.
- Trial name
- NCT07720310
- Testing
- CAR T cells chimeric antigen receptor cells
- Where
- Belarus
- Volunteers
- 12 people
- Sponsor
- N.N. Alexandrov National Cancer Centre
Lupus Erythematosus, Systemic, Sjogren's Syndrome
Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome
The purpose of the study is to examine whether dehydroepiandrosterone (DHEA) administration improves fatigue and general well-being in patients with systemic lupus erythematosus or primary Sjögren's syndrome
- Trial name
- NCT00391924
- Testing
- Dehydroepiandrosterone
- Where
- 2 sites in Netherlands
- Volunteers
- 120 people
- Sponsor
- UMC Utrecht
Lupus Nephritis, Systemic Lupus Erythematosus (SLE)
Assessing Residual Inflammation and Macrophage Presence in Lupus Nephritis After 3 Months of Intensified Treatment With Prednisolone, Mycofenolate Mofetil and Voclosporin as Compared to Mycofenolate Mofetil and Prednisolone
The goal of this clinical trial is to learn how different treatments affect immune cells in the kidney in people with active lupus nephritis (LN), a kidney manifestation of systemic lupus erythematosus (SLE).
- Trial name
- MAPLE (NCT07760480)
- Testing
- Kidney Biopsy, Voclosporin (LUPKYNIS), Blood, feces and urine sample collection
- Where
- Netherlands
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Lupus Erythematosus, Systemic
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE).
- Trial name
- TOPAZ-1 (NCT04895241)
- Testing
- Litifilimab
- Where
- 164 sites in United States, Australia and 13 more
- Volunteers
- 548 people
- Sponsor
- Biogen
Systemic Lupus Erythematosus
Ultraviolet Light Therapy for Systemic Lupus Erythematosus
OBJECTIVES: I. Evaluate the mechanisms of ultraviolet A-1 light therapy in patients with systemic lupus erythematosus and normal controls.
- Trial name
- NCT00004375
- Testing
- ultraviolet A-1 light treatment
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Center for Research Resources (NCRR)
SLE
Relation of Antibodies Against Oxidized Low Density Lipoproteins to Disease Activity and Cardiovascular Affection in Systemic Lupus.
The aim of this study is to correlate the autoantibody against oxidized LDL with disease activity and cardiovascular affection in patients with SLE.
- Trial name
- NCT05479071
- Testing
- Blood test
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Systemic Lupus Erythematosus
A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus
The purpose of this study is to evaluate the efficacy and safety of IMC-002 and IMM0306S in the treatment of active SLE.
- Trial name
- NCT06535412
- Testing
- IMC-002 + SOC, IMM0306S + SOC
- Where
- China
- Volunteers
- 218 people
- Sponsor
- ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Lupus Nephritis, Membranous Nephropathy
Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial
Lupus nephritis (LN) is a frequent and severe complication of systemic lupus erythematosus, with important mortality and morbidity.
- Trial name
- OBLUMEN (NCT07721363)
- Testing
- Obinutuzumab
- Where
- France
- Volunteers
- 65 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Lupus Erythematosus
WEUKBRE5716: Steroid-related Damage in Systemic Lupus Erythematosus (Hopkins)
The study is designed to assess the association between steroid exposure and five potentially steroid-related adverse events within a cohort of individuals with systemic lupus erythematosus (SLE).
- Trial name
- NCT01616472
- Testing
- Cumulative corticosteroid exposure
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Systemic Lupus Erythematosus
PRV-3279-2a Trial in Systemic Lupus
The PREVAIL-2 study was designed to assess the safety and potential efficacy of PRV-3279 in flare prevention in systemic lupus erythematosus (SLE) participants with active disease after amelioration induced by corticosteroid…
- Trial name
- PREVAIL-2 (NCT05087628)
- Testing
- PRV-3279
- Where
- 36 sites in United States, China and 2 more
- Volunteers
- 28 people
- Sponsor
- Provention Bio, a Sanofi Company
Uromodulin, SLE
Uromodulin as a Biomarker in Lupus Nephritis
Evaluation of Uromodulin as a biomarker of renal histological activity/ Chronicity indices in lupus nephritis
- Trial name
- NCT07763834
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Assiut University
SLE
A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
To evaluate the safety, tolerability, pharmacokinetics and pharmacokinetics of multi-dose APG-2575 in mild-to-moderate systemic lupus erythematosus (SLE).
- Trial name
- NCT06182969
- Testing
- APG-2575
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ascentage Pharma Group Inc.
Lupus Erythematosus, Systemic
Allogeneic Blood Stem Cell Transplantation for Patients With Life-Threatening Systemic Lupus Erythematosus
The Stanford Medical Center Division of Immunology and Rheumatology and the Division of Blood and Marrow Transplantation (BMT) are enrolling patients with severe systemic lupus erythematosus (SLE) that is resistant to standard…
- Trial name
- SLE (NCT00325741)
- Testing
- Hematopoietic Cell Transplantation
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Stanford University
Lupus Erythematosus, Systemic
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cevostamab in participants with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN).
- Trial name
- NCT07629583
- Testing
- Cevostamab, Tocilizumab
- Where
- 2 sites in France, Spain
- Volunteers
- 46 people
- Sponsor
- Genentech, Inc.